– GUERNSEY, St. Peter Port – Syncona Ltd (LON: SYNC), a leading healthcare company focused on founding, building, and funding global leaders in life science, today announced the appointment of Board member Virginia Holmes as the Senior Independent Director, effective from 1 January 2022.
The company also announced that Nigel Keen and Nicholas Moss step down as Non-Executive Directors on 31 December 2021.
About Syncona
Syncona’s purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.
Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies, and deliver strong risk-adjusted returns to shareholders.
For more information: https://www.synconaltd.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.